Ex vivo treatment of malignant pleural effusions with the bispecific antibody MT110 targeting EPCAM and CD3

被引：0
|
作者：
Witthauer, J. [1 ,2 ]
Schlereth, B. [2 ]
Brischwein, K. [2 ]
Jauch, K. -W. [1 ]
Mayer, B. [1 ]
机构：
[1] Univ Munich, LMU, Dept Surg, Munich, Germany
[2] Micromet AG, Munich, Germany
来源：
ONKOLOGIE | 2008年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：56 / 56
页数：1
相关论文
共 50 条
  • [1] Eradication of colon cancer stem cells by EpCAM/CD3-bispecific BiTE antibody MT110
    Munz, Markus
    Herrmann, Ines
    Friedrich, Matthias
    Murr, Alexander
    Kufer, Peter
    Baeuerle, Patrick A.
    Raum, Tobias
    CANCER RESEARCH, 2009, 69
  • [2] A phase I study of EpCAM/CD3-bispecific antibody (MT110) in patients with advanced solid tumors
    Fiedler, Walter M.
    Wolf, Martin
    Kebenko, Maxim
    Goebeler, Marie-Elisabeth
    Ritter, Barbara
    Quaas, Alexander
    Vieser, Eva
    Hijazi, Youssef
    Patzak, Ingrid
    Friedrich, Matthias
    Kufer, Peter
    Frankel, Stanley
    Seggewiss-Bernhardt, Ruth
    Kaubitzsch, Sabine
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] Functional importance of EpCAM for the activity of tumor-initiating cancer cells and their eradication by EpCAM/CD3-bispecific antibody MT110
    Muenz, Markus
    Herrmann, Ines
    Friedrich, Matthias
    Murr, Alexander
    Kufer, Peter
    Baeuerle, Patrick A.
    Raum, Tobias
    CANCER RESEARCH, 2011, 71
  • [4] Safety and pharmacology of the EpCAM/CD3-bispecific BiTE antibody MT110 in patients with metastatic colorectal, gastric or lung cancer
    Fiedler, W.
    Hoenemann, D.
    Ritter, B.
    Bokemeyer, C.
    Fettes, P.
    Klinger, M.
    Reinhardt, C.
    Zugmaier, G.
    Kaubitzsch, S.
    Wolf, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 136 - 137
  • [5] Characterization of a murine EpCAM/CD3-bispecific BITE molecule as a surrogate for preclinical development of the human EpCAM/CD3-bispecific BITE molecule MT110
    Schlereth, B.
    Brischwein, K.
    Lutterbuese, P.
    Parr, L.
    Lorenczewski, G.
    Aman, M.
    Kischel, R.
    Kufer, P.
    Locher, M.
    Baeuerle, P. A.
    EJC SUPPLEMENTS, 2006, 4 (12): : 70 - 70
  • [6] Targeting Pleural Carcinoma Cells with the Anti-EpCAM BiTE Antibody MT110 by Stimulating Microenvironment T Cells
    Mayer, B.
    Witthauer, J.
    Winter, H.
    Funke, I
    Baeuerle, P.
    Jauch, K-W
    CANCER RESEARCH, 2009, 69 (24) : 751S - 752S
  • [7] A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors
    Kebenko, Maxim
    Goebeler, Marie-Elisabeth
    Wolf, Martin
    Hasenburg, Annette
    Seggewiss-Bernhardt, Ruth
    Ritter, Barbara
    Rautenberg, Beate
    Atanackovic, Djordje
    Kratzer, Andrea
    Rottman, James B.
    Friedrich, Matthias
    Vieser, Eva
    Elm, Stefanie
    Patzak, Ingrid
    Wessiepe, Dorothea
    Stienen, Sabine
    Fiedler, Walter
    ONCOIMMUNOLOGY, 2018, 7 (08):
  • [8] EpCAM/CD3-Bispecific T-cell Engaging Antibody MT110 Eliminates Primary Human Pancreatic Cancer Stem Cells
    Cioffi, Michele
    Dorado, Jorge
    Baeuerle, Patrick A.
    Heeschen, Christopher
    CLINICAL CANCER RESEARCH, 2012, 18 (02) : 465 - 474
  • [9] Phase I safety and pharmacology study of the EpCAM/CD3-bispecific BiTE antibody MT110 in patients with metastatic colorectal, gastric, or lung cancer
    Fledler, W. M.
    Ritter, B.
    Seggewiss, R.
    Bokemeyer, C.
    Fettes, P.
    Klinger, M.
    Vieser, E.
    Ruettinger, D.
    Kaubitzsch, S.
    Wolf, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] Efficacy of Bispecific Antibody Targeting EpCAM and CD3 for Immunotherapy in Ovarian Cancer Ascites: An Experimental Study
    Li, Yi-nuo
    Li, Yuan-yuan
    Wang, Shi-xuan
    Ma, Xiang-yi
    CURRENT MEDICAL SCIENCE, 2023, 43 (03) : 539 - 550
12345